Most analysts love Pfizer, which has an average rating of buy. But there's reason to believe the stock may be overvalued at today's price of $26.57 per share. Let's look at the fundamentals ourselves and see if we reach a different conclusion than the analyst community.
Pfizer has a P/E ratio of 35.4 based on its 12 month trailing earnings per share of $0.75. Considering its future earnings estimates of $2.93 per share, the stock's forward P/E ratio is 9.1. In comparison, the average P/E ratio of the Health Care sector is 26.07 and the average P/E ratio of the S&P 500 is 29.3.
We can also compare the ratio of Pfizer's market price to its book value, which gives us the price to book, or P/B ratio. A company's book value refers to its present equity value -- or what is left over when we subtract its liabilities from its assets. PFE has a P/B ratio of 1.63, with any figure close to or below one indicating a potentially undervalued company.
A comparison of the share price versus company earnings and book value should be balanced by an analysis of the company's ability to pay its liabilities. One popular metric is the Quick Ratio, or Acid Test, which is the company's current assets minus its inventory and prepaid expenses divided by its current liabilities. Pfizer's quick ratio is 0.64. Generally speaking, a quick ratio above 1 signifies that the company is able to meet its liabilities.
The final element of our analysis will touch on Pfizer's ability to generate cash for the benefit of its shareholders or for reinvesting in the business. For this, we look at the company's levered free cash flow, which is the sum of all incoming and outgoing cash flows, including the servicing of current debt and liabilities. Pfizer has a free cash flow of $4.79 Billion, which it uses to pay its shareholders a 6.3% dividend.
At Market Inference, we will keep monitoring Pfizer to see if the analysts were right to recommend the stock despite its valuation issues. We recognize that numbers don't always tell the whole story, and that qualitative factors often set high performing investments apart from the rest.
